Cargando…

Screening of germline mutations in young Rwandan patients with breast cancers

BACKGROUND: In Sub‐Saharan Africa breast cancer is commonly detected at younger age and the profile is more aggressive with a high mortality rate compared to the European countries. It is suggested that African‐specific genetic background plays a key role in this matter. The present study aimed at u...

Descripción completa

Detalles Bibliográficos
Autores principales: Uyisenga, Jeanne P., Segers, Karin, Lumaka, Aimé Z., Mugenzi, Pacifique, Fasquelle, Corinne, Boujemila, Bouchra, Josse, Claire, Mutesa, Leon, Bours, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667342/
https://www.ncbi.nlm.nih.gov/pubmed/32959997
http://dx.doi.org/10.1002/mgg3.1500
_version_ 1783610292512489472
author Uyisenga, Jeanne P.
Segers, Karin
Lumaka, Aimé Z.
Mugenzi, Pacifique
Fasquelle, Corinne
Boujemila, Bouchra
Josse, Claire
Mutesa, Leon
Bours, Vincent
author_facet Uyisenga, Jeanne P.
Segers, Karin
Lumaka, Aimé Z.
Mugenzi, Pacifique
Fasquelle, Corinne
Boujemila, Bouchra
Josse, Claire
Mutesa, Leon
Bours, Vincent
author_sort Uyisenga, Jeanne P.
collection PubMed
description BACKGROUND: In Sub‐Saharan Africa breast cancer is commonly detected at younger age and the profile is more aggressive with a high mortality rate compared to the European countries. It is suggested that African‐specific genetic background plays a key role in this matter. The present study aimed at understanding the role of genetic factors in breast cancer development in young Rwandan. METHODS: We performed a massive parallel sequencing on Illumina MiSeq NGS system for the screening of 26 genes associated with hereditary breast cancer from 40 patients under 35 years old from two University Teaching Hospitals in Kigali, Rwanda. Sanger sequencing was used to confirm pathogenic and likely pathogenic mutations. RESULTS: Five patients out of 40 (12.5%) presented with pathogenic mutations including four patients (10%) carrying BRCA1 or BRCA2 pathogenic variants. One patient showed a missense likely pathogenic TP53 variant. We have also detected additional missense, intronic, and 3’UTR variants of unknown significance in all study participants. CONCLUSION: This preliminary study suggests that the frequency of germline mutations in young Rwandan patients with breast cancer is similar to the observations made in Caucasians. However, further large studies including patients and controls are needed to better understand the impact of genetic factors as well as the environmental risk factors in the development of breast cancer in young Rwandans.
format Online
Article
Text
id pubmed-7667342
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76673422020-11-20 Screening of germline mutations in young Rwandan patients with breast cancers Uyisenga, Jeanne P. Segers, Karin Lumaka, Aimé Z. Mugenzi, Pacifique Fasquelle, Corinne Boujemila, Bouchra Josse, Claire Mutesa, Leon Bours, Vincent Mol Genet Genomic Med Original Articles BACKGROUND: In Sub‐Saharan Africa breast cancer is commonly detected at younger age and the profile is more aggressive with a high mortality rate compared to the European countries. It is suggested that African‐specific genetic background plays a key role in this matter. The present study aimed at understanding the role of genetic factors in breast cancer development in young Rwandan. METHODS: We performed a massive parallel sequencing on Illumina MiSeq NGS system for the screening of 26 genes associated with hereditary breast cancer from 40 patients under 35 years old from two University Teaching Hospitals in Kigali, Rwanda. Sanger sequencing was used to confirm pathogenic and likely pathogenic mutations. RESULTS: Five patients out of 40 (12.5%) presented with pathogenic mutations including four patients (10%) carrying BRCA1 or BRCA2 pathogenic variants. One patient showed a missense likely pathogenic TP53 variant. We have also detected additional missense, intronic, and 3’UTR variants of unknown significance in all study participants. CONCLUSION: This preliminary study suggests that the frequency of germline mutations in young Rwandan patients with breast cancer is similar to the observations made in Caucasians. However, further large studies including patients and controls are needed to better understand the impact of genetic factors as well as the environmental risk factors in the development of breast cancer in young Rwandans. John Wiley and Sons Inc. 2020-09-22 /pmc/articles/PMC7667342/ /pubmed/32959997 http://dx.doi.org/10.1002/mgg3.1500 Text en © 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Uyisenga, Jeanne P.
Segers, Karin
Lumaka, Aimé Z.
Mugenzi, Pacifique
Fasquelle, Corinne
Boujemila, Bouchra
Josse, Claire
Mutesa, Leon
Bours, Vincent
Screening of germline mutations in young Rwandan patients with breast cancers
title Screening of germline mutations in young Rwandan patients with breast cancers
title_full Screening of germline mutations in young Rwandan patients with breast cancers
title_fullStr Screening of germline mutations in young Rwandan patients with breast cancers
title_full_unstemmed Screening of germline mutations in young Rwandan patients with breast cancers
title_short Screening of germline mutations in young Rwandan patients with breast cancers
title_sort screening of germline mutations in young rwandan patients with breast cancers
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667342/
https://www.ncbi.nlm.nih.gov/pubmed/32959997
http://dx.doi.org/10.1002/mgg3.1500
work_keys_str_mv AT uyisengajeannep screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT segerskarin screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT lumakaaimez screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT mugenzipacifique screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT fasquellecorinne screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT boujemilabouchra screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT josseclaire screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT mutesaleon screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers
AT boursvincent screeningofgermlinemutationsinyoungrwandanpatientswithbreastcancers